… -daily administration of 300 mg of nirmatrelvir plus 100 mg of … 90% effective concentration
of nirmatrelvir (ie, the concentration … of nirmatrelvir plus ritonavir in nonhospitalized adults with …

… The effects of nirmatrelvir/ritonavir (NMV/r [Paxlovid]) on coronavirus disease 2019 (COVID-…
adults are unclear. The objective of this study was to assess if NMV/r use in vaccinated adults …

… The new oral antiviral paxlovid consists of two active drugs: nirmatrelvir (PF-07321332), which
acts … of HIV, used to slow the metabolism of nirmatrelvir. Paxlovid is authorized in 150 mg …

… Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r)
in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe …

… or remdesivir in non-hospitalized patients with mild-… nirmatrelvir/ritonavir, 30% for molnupiravir,
and 87% for remdesivir, respectively [Citation24]. Therefore, in this setting oral nirmatrelvir…

… the effectiveness of nirmatrelvir/ritonavir and molnupiravir versus no oral antiviral treatment
in reducing severe clinical outcomes among non-hospitalized adults stratified by their COVID-…

… To the Editor: Nirmatrelvir is a promising orally administered antiviral agent against … nirmatrelvir
treatment foundational to their Covid-19 strategy.Ideally, early treatment with nirmatrelvir (…

… three pills (two of nirmatrelvir and one of ritonavir) … nirmatrelvir/ritonavir (Paxlovid ® ) is still
awaited. The first regulatory approvals of molnupiravir and nirmatrelvir/ritonavir as the first oral …

… Nirmatrelvir is an orally administered antiviral agent that … with at least one risk factor for
severe Covid-19, nirmatrelvir–… and safety of nirmatrelvir–ritonavir in nonhospitalized adults with …

… and virologic outcomes associated with molnupiravir and nirmatrelvir/ritonavir use in COVID-…
While both oral antivirals are now indicated for non-hospitalized COVID-19 patients who are …